AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation

Launched by RIGSHOSPITALET, DENMARK · Feb 23, 2024

Keywords

ClinConnect Summary

The AlloCare clinical trial is looking at how to support and manage the long-term effects that some patients experience after receiving a special type of blood stem cell transplant called allogeneic hematopoietic stem cell transplantation (allo-HSCT). This trial will test a new program designed to help survivors deal with these late effects. It will involve two groups of participants to see how well the program works.

To be eligible for this trial, participants must be adults over 18 who have undergone either a myeloablative (a type of treatment that wipes out bone marrow) or non-myeloablative stem cell transplant and are currently being monitored for their health without any signs of cancer coming back. Unfortunately, those who have had their cancer return, are facing new cancer treatments, or do not have access to email and the internet cannot participate. If you join the trial, you can expect to receive support tailored to help you manage any ongoing health issues related to your transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (age\> 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion.
• Exclusion Criteria:
• • Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded.